The ‘ Artificial Intelligence For Drug Development and Discovery market’ research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market overview; Artificial Intelligence For Drug Development and Discovery derived key statistics, based on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in Artificial Intelligence For Drug Development and Discovery market size forecast, Get report to understand the structure of the complete fine points (Including Full TOC, List of Tables & Figures, Chart).
Download Free Sample Copy of ‘Artificial Intelligence For Drug Development and Discovery market’ Report @
https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR1016
A combination of factors, including COVID-19 containment situation, end-use market recovery & Recovery Timeline of 2020/ 2021
| covid-19 scenario | Market Behavior/ Level of Risk and Opportunity | End Industry Behavior/ Opportunity Assessment | Expected Industry Recovery Timeline | Business Impact Horizon |
| Opening of Economy by Q3 2020 | xx | xx | xx | xx |
| Recovery – Opening of Economy extended till Q4 2020 / Q1 2021 | xx | xx | xx | xx |
The artificial intelligence for drug discovery and development market was valued at $520 million in 2019 and is projected to reach $4,815 million by 2027, registering a CAGR of 31.6% from 2020 to 2027.
Artificial intelligence (AI) is science and engineering adopted to design intelligent machines, especially intelligent computer programs. AI is an intelligent system that relates various human intelligence based functions such as reasoning, learning, and problem-solving skills on different disciplines such as biology, computer science, psychology, mathematics, linguistics, and engineering. In the healthcare industry, AI is applicable in medication management, treatment plans, drug discovery& developments and others.
Drug discovery& development includes several processes and phases that demand a huge amount of funds. Furthermore, clinical trials and approval of the drug in the market might be a challenging task. Increase in number of collaborations between pharmaceutical & biotech companies and AI providers are the major driver for this market. Artificial intelligence decreases a large amount of time and cost utilized in the drug discovery and development process, which is mainly influencing the market growth. The increasing demand for cloud-based software that enables the researcher to design drugs quickly and accurately is expected to drive the market growth. Moreover, the integration of artificial intelligence (AI) and machine learning approaches within the life science R&D industry is making drug discovery and development more innovative, time-effective and cost-effective.
The artificial intelligence for drug discovery and development market is segmented on the type, indication, end user and region. By type, it is divided into target identification, molecules screening, de novo drug design &drug optimization and preclinical &clinical testing. On the basis of indication, it is classified into oncology, infectious disease, neurology, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, and CROs.
Region wise, the market is analyzed across North America (US, Canada), Europe (Germany, France, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).North America held the major share of the artificial intelligence for drug discovery and development market in 2019 and is expected to continue its dominance during the forecast period, owing to strong economies in the U.S. and Canada; high adoption rate of AI technologies due to large number of investments to boost the drug discovery industry; and large number of cross industry collaborations and partnerships majorly fuels the market growth. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of advanced AI technologies, and growth in focus of major players on increasing their presence in emerging Asian countries.
KEY MARKET SEGMENTS
By Type
– Target Identification
– Molecule Screening
– De Novo Drug Design and Drug Optimization
– Preclinical and Clinical Testing
By Indication
– Oncology
– Infectious Disease
– Neurology
– Others
By End User
– Pharmaceutical and Biotechnology Companies.
– Contract Research Organization (CROs).
LIST OF KEY PLAYERS PROFILED IN THE REPORT
– Alphabet Inc.
– Atomwise, Inc
– Benevolent AI
– Cloud Pharmaceutical
– Deep Genomics
– Exscientia
– Insilico Medicine Inc.
– Microsoft Corporation
– Nvidia Corporation
A systematic step framework for How to Tackle The Situation… “MITIGATE” | “SUSTAIN” | “GROW”: Business Strategy Recovery, Scenario and Planning
Key Segments Studied in the Global Artificial Intelligence For Drug Development and Discovery Market
Geographical Breakdown: Regional level analysis of the market, currently covering North America, Europe, China & Japan
In-Depth Qualitative Analyses Include Identification And Investigation Of The Following Aspects: Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porter’s Fiver Forces. The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The report basically gives information about the Market trends, growth factors, limitations, opportunities, challenges, future forecasts, and details about all the key market players.
(Check Our Exclusive Offer: Ask for Discount to our Representative)
https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR1016
Changing Forecasts in a Time of Crisis: explores key issues, including:
- The heavy economic impacts of social distancing measures
- Future changes in consumer behavior
- The urgent need for high-frequency economic data
- Mapping Out a Potential Recovery
- Business Strategies During COVID-19
- Near & Long Term Risk Outlook, Risk Assessment and Opportunities
Key questions answered: Study Explore COVID 19 Outbreak Impact Analysis
- Market size and growth rate during forecast period.
- Key factors driving the Market.
- Key market trends cracking up the growth of the Market.
- Challenges to market growth.
- Key vendors of Market.
- Detailed SWOT analysis.
- Opportunities and threats faces by the existing vendors in Global Market.
- Trending factors influencing the market in the geographical regions.
- Strategic initiatives focusing the leading vendors.
- PEST analysis of the market in the five major regions.
- What should be entry strategies, countermeasures to economic impact, and marketing channels?
- What are market dynamics?
- What are challenges and opportunities?
- What is economic impact on market?
- What is market chain analysis by upstream raw materials and downstream industry?
- What is industry considering capacity, production and production value? What will be the estimation of cost and profit? What will be market share, supply and consumption? What about import and export?
- What is current market status? What’s market competition in this industry, both company, and country wise? What’s market analysis by taking applications and types in consideration?
- What were capacity, production value, cost and profit?
- Who are the global key players in this industry? What are their company profile, their product information, and contact information?
- Which manufacturing technology is used, what are their company profile, their product information, and contact information?
Ask Our Expert for Complete Report@:
https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR1016
Key Points Covered in Artificial Intelligence For Drug Development and Discovery Market Report: COVID 19 Impact Analysis
CHAPTER 1: INTRODUCTION
1.1. Report description
1.1. Key benefits for stakeholders
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2019
3.4. Porter’s five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Growing number of cross industry collaborations and partnerships
3.5.1.2. Artificial intelligence reduces cost and time utilized in the drug discovery& development process.
3.5.2. Restraints
3.5.2.1. Lack of skilled professionals
3.5.2.2. Lack of data sets in the field of drug discovery
3.5.3. Opportunity
3.5.3.1. Increase in awareness related to artificial intelligence
3.5.3.2. Untapped market in developing regions
3.5.4. Impact Analysis
CHAPTER 4: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Target Identification
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Molecule Screening
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. De Novo Drug Design and Drug Optimization
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Preclinical and clinical testing
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Neurology
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Infectious Disease
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
CHAPTER 6: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical and biotechnology companies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Contract Research Organization
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America artificial intelligence for drug discovery and development , by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. artificial intelligence for drug discovery and development market, by type
7.2.2.1.2. U.S artificial intelligence for drug discovery and development market, by indication
7.2.2.1.3. U.S. artificial intelligence for drug discovery and development market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada artificial intelligence for drug discovery and development market, by type
7.2.2.2.2. Canada artificial intelligence for drug discovery and development market, by indication
7.2.2.2.3. Canada artificial intelligence for drug discovery and development market, by end user
7.2.3. North America artificial intelligence for drug discovery and development market, by type
7.2.4. North America artificial intelligence for drug discovery and development , by indication
7.2.5. North America artificial intelligence for drug discovery and development , by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe artificial intelligence for drug discovery and development , by country
7.3.2.1. UK artificial intelligence for drug discovery and development market, by type
7.3.2.1.1. UK artificial intelligence for drug discovery and development market, by type
7.3.2.1.2. UK artificial intelligence for drug discovery and development market, by indication
7.3.2.1.3. UK artificial intelligence for drug discovery and development market, by end user
7.3.2.2. Germany
7.3.2.2.1. Germany artificial intelligence for drug discovery and development market, by type
7.3.2.2.2. Germany artificial intelligence for drug discovery and development market, by indication
7.3.2.2.3. Germany artificial intelligence for drug discovery and development market, by end user
7.3.2.3. France
7.3.2.3.1. France artificial intelligence for drug discovery and development market, by type
7.3.2.3.2. France artificial intelligence for drug discovery and development market, by indication
7.3.2.3.3. France artificial intelligence for drug discovery and development market, by end user
7.3.2.4. Rest of Europe
7.3.2.4.1. Rest of Europe artificial intelligence for drug discovery and development market, by type
7.3.2.4.2. Rest of Europe artificial intelligence for drug discovery and development market, by indication
7.3.2.4.3. Rest of Europe artificial intelligence for drug discovery and development market, by end user
7.3.3. Europe artificial intelligence for drug discovery and development , by type
7.3.4. Europe artificial intelligence for drug discovery and development , by indication
7.3.5. Europe artificial intelligence for drug discovery and development , by end user
7.4. Asia-pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific artificial intelligence for drug discovery and development , by country
7.4.2.1. Japan
7.4.2.1.1. Japan artificial intelligence for drug discovery and development market, by type
7.4.2.1.2. Japan artificial intelligence for drug discovery and development market, by indication
7.4.2.1.3. Japan artificial intelligence for drug discovery and development market, by end user
7.4.2.2. China
7.4.2.2.1. China artificial intelligence for drug discovery and development market, by type
7.4.2.2.2. China artificial intelligence for drug discovery and development market, by indication
7.4.2.2.3. China artificial intelligence for drug discovery and development market, by end user
7.4.2.3. Australia
7.4.2.3.1. .Australia artificial intelligence for drug discovery and development market, by type
7.4.2.3.2. Australia artificial intelligence for drug discovery and development market, by indication
7.4.2.3.3. Australia artificial intelligence for drug discovery and development market, by end user
7.4.2.4. India
7.4.2.4.1. India artificial intelligence for drug discovery and development market, by type
7.4.2.4.2. India artificial intelligence for drug discovery and development market, by indication
7.4.2.4.3. India artificial intelligence for drug discovery and development market, by end user
7.4.2.5. Rest of Asia-Pacific
7.4.2.5.1. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by type
7.4.2.5.2. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by indication
7.4.2.5.3. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by end user
7.4.3. Asia-Pacific artificial intelligence for drug discovery and development , by type
7.4.4. Asia-Pacific artificial intelligence for drug discovery and development , by indication
7.4.5. Asia-Pacific artificial intelligence for drug discovery and development , by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA artificial intelligence for drug discovery and development , by country
7.5.2.1. Latin America
7.5.2.1.1. Latin America artificial intelligence for drug discovery and development market, by type
7.5.2.1.2. Latin America artificial intelligence for drug discovery and development market, by indication
7.5.2.1.3. Latin America artificial intelligence for drug discovery and development market, by end user
7.5.2.2. Middle east and Africa
7.5.2.2.1. Middle east and Africa artificial intelligence for drug discovery and development market, by type
7.5.2.2.2. Middle east and Africa artificial intelligence for drug discovery and development market, by indication
7.5.2.2.3. Middle east and Africa artificial intelligence for drug discovery and development market, by end user
CHAPTER 8: COMPANY PROFILES
8.1. ALPHABET INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ATOMWISE, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segment
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. BENEVOLENT AI
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segment
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments
8.4. CLOUD PHARMACEUTICAL
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. DEEP GENOMICS
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segment
8.5.4. Product portfolio
8.6. EXSCIENTIA.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. IBM CORPORATION
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. INSILICO MEDICINE INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segment
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. MICROSOFT CORPORATION
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. NVIDIA CORPORATION
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Continued….
……..and view more in complete table of Contents
Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR1016
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.
Contact Information:
Get in Touch with Us:
Report Ocean
Email: sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website: https://www.reportocean.com/
Blog: https://reportoceanblog.com/
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English
Contact Information:
Get in Touch with Us:
Report Ocean
Email: sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website: https://www.reportocean.com/
Blog: https://reportoceanblog.com/